We are live on ! Find out more
MVM

Medicxi Ventures Management Portfolio holdings

AUM $982M
1-Year Est. Return 210.17%
This Fund
S&P 500
This Quarter Est. Return
+47.69%
1 Year Est. Return
+210.17%
3 Year Est. Return
+787.54%
5 Year Est. Return
+404.19%
10 Year Est. Return
–
AUM
$449M
AUM Growth
+$153M
Cap. Flow
+$14M
Cap. Flow %
3.11%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
PHAT icon
Phathom Pharmaceuticals
PHAT
+$31.5M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$17.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTA
1
DELISTED
Centessa Pharmaceuticals
CNTA
$226M 50.22%
19,963,157
– –
PHAT icon
2
Phathom Pharmaceuticals
PHAT
$708M
$79.3M 17.65%
7,464,572
+3,703,703
+98% +$31.5M
NAMS icon
3
NewAmsterdam Pharma
NAMS
$3.25B
$67.9M 15.11%
2,869,565
– –
MRUS
4
DELISTED
Merus
MRUS
$52.6M 11.72%
1,169,028
-430,972
-27% -$17.5M
AURA icon
5
Aura Biosciences
AURA
$725M
$23.9M 5.31%
3,039,892
– –

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
FFS
Forge Financial Services Edmond, Oklahoma $987M AUM 14.12% 1-Year Est. Return
PCM
Polymer Capital Management New York $988M AUM 56.33% 1-Year Est. Return
RCG
Rock Creek Group Washington, District of Columbia $988M AUM 8.89% 1-Year Est. Return

Medicxi Ventures Management's Q1 2024 Portfolio in Review

As of Q1 2024, Medicxi Ventures Management held 5 positions worth $449M, up 52% from $296M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Medicxi Ventures Management deployed $14M of net new capital in Q1 2024, adding to 1 existing holding.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Merus, an estimated $17.5M trimmed.

  • Medicxi Ventures Management added most to Phathom Pharmaceuticals in Q1 2024, an estimated $31.5M increase.
  • Medicxi Ventures Management's biggest Q1 2024 reduction was Merus, cutting an estimated $17.5M.
  • Medicxi Ventures Management's ten largest holdings make up 100% of its $449M portfolio in Q1 2024.
  • Medicxi Ventures Management opened 0 new positions and closed 0 in Q1 2024.
  • Medicxi Ventures Management's portfolio value rose 52% quarter-over-quarter to $449M.

Based on Medicxi Ventures Management's 13F filing for Q1 2024, filed 15 Apr 2024.